Compile Data Set for Download or QSAR

Found 769 hits of ic50 for UniProtKB: P00750   

Target/Host (Institution)	Ligand	Target/Host Links	Ligand Links	Trg + Lig Links	Ki nM	ΔG° kcal/mole	IC50 nM	Kd nM	EC50/IC50 nM	koff s-1	kon M-1s-1	pH	Temp °C
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM50120225 (2-{[2-(4-Guanidino-butyrylamino)-3-(4-nitro-phenyl...) Show SMILES CC(O)C(N(C)C(=O)C(Cc1ccc(cc1)[N+]([O-])=O)NC(=O)CCC[N-]C(N)=[NH2+])C(=O)NC(C)c1ccccc1 Show InChI InChI=1S/C27H37N7O6/c1-17(20-8-5-4-6-9-20)31-25(37)24(18(2)35)33(3)26(38)22(32-23(36)10-7-15-30-27(28)29)16-19-11-13-21(14-12-19)34(39)40/h4-6,8-9,11-14,17-18,22,24,35H,7,10,15-16H2,1-3H3,(H6,28,29,30,31,32,36,37)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	n/a	n/a	0.700	n/a	n/a	n/a	n/a	n/a	n/a
Bristol-Myers Squibb Pharmaceutical Research Institute Curated by ChEMBL					Assay Description Concentration of the compound required to inhibit tissue-type plasminogen activator (t-PA) was determined				Bioorg Med Chem Lett 12: 3183-6 (2002) BindingDB Entry DOI: 10.7270/Q20P0ZBK
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298092 (3-[3-(2-tert-butoxyethyl)-1,2,4-oxadiazol-5-yl]-2-...) Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(CCOC(C)(C)C)no1)C1CCNCC1 Show InChI InChI=1S/C20H28N6O3/c1-12-17(19-22-15(25-29-19)7-10-28-20(2,3)4)18-23-16(27)11-14(26(18)24-12)13-5-8-21-9-6-13/h11,13,21H,5-10H2,1-4H3,(H,23,27)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	6	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298254 (3-(2-methylbutanoyl)-7-(piperidin-4-yl)pyrazolo[1,...) Show SMILES CCC(C)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	8	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298255 (3-(cyclopropylcarbonyl)-7-(piperidin-4-yl)pyrazolo...) Show SMILES O=C(C1CC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C15H18N4O2/c20-13-7-12(9-3-5-16-6-4-9)19-15(18-13)11(8-17-19)14(21)10-1-2-10/h7-10,16H,1-6H2,(H,18,20)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	8	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM92479 (Tannic Acid, A | Tannic acid) Show SMILES Oc1cc(cc(O)c1O)C(=O)Oc1cc(cc(O)c1O)C(=O)OCC1OC(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C(OC(=O)c2cc(O)c(O)c(OC(=O)c3cc(O)c(O)c(O)c3)c2)C1OC(=O)c1cc(O)c(O)c(OC(=O)c2cc(O)c(O)c(O)c2)c1 Show InChI InChI=1S/C76H52O46/c77-32-1-22(2-33(78)53(32)92)67(103)113-47-16-27(11-42(87)58(47)97)66(102)112-21-52-63(119-72(108)28-12-43(88)59(98)48(17-28)114-68(104)23-3-34(79)54(93)35(80)4-23)64(120-73(109)29-13-44(89)60(99)49(18-29)115-69(105)24-5-36(81)55(94)37(82)6-24)65(121-74(110)30-14-45(90)61(100)50(19-30)116-70(106)25-7-38(83)56(95)39(84)8-25)76(118-52)122-75(111)31-15-46(91)62(101)51(20-31)117-71(107)26-9-40(85)57(96)41(86)10-26/h1-20,52,63-65,76-101H,21H2	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase KEGG PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	8	n/a	n/a	n/a	n/a	7.8	23
University of Michigan					Assay Description Enzyme activity assay using human and murine PAI-1.				J Biol Chem 285: 7892-902 (2010) Article DOI: 10.1074/jbc.M109.067967 BindingDB Entry DOI: 10.7270/Q2ZC81FC
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298041 (3-(2-methyl-1,3-thiazol-5-yl)-7-(piperidin-4-yl)py...) Show SMILES Cc1ncc(s1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C15H17N5OS/c1-9-17-8-13(22-9)11-7-18-20-12(6-14(21)19-15(11)20)10-2-4-16-5-3-10/h6-8,10,16H,2-5H2,1H3,(H,19,21)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	8.20	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297950 (7-(piperidin-4-yl)-3-{5-[4-(trifluoromethyl)phenyl...) Show SMILES FC(F)(F)c1ccc(cc1)-c1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C20H17F3N6O2/c21-20(22,23)13-3-1-12(2-4-13)18-27-28-19(31-18)14-10-25-29-15(9-16(30)26-17(14)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	8.70	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298115 (7-(piperidin-4-yl)-3-(piperidin-1-ylcarbonyl)pyraz...) Show SMILES O=C(N1CCCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C17H23N5O2/c23-15-10-14(12-4-6-18-7-5-12)22-16(20-15)13(11-19-22)17(24)21-8-2-1-3-9-21/h10-12,18H,1-9H2,(H,20,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298123 (3-(4-cyclohexyl-1,3-thiazol-2-yl)-7-(piperidin-4-y...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3nc(cs3)C3CCCCC3)c2[nH]1 Show InChI InChI=1S/C20H25N5OS/c26-18-10-17(14-6-8-21-9-7-14)25-19(24-18)15(11-22-25)20-23-16(12-27-20)13-4-2-1-3-5-13/h10-14,21H,1-9H2,(H,24,26)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM50029498 (1N-[2-{2-[4-amino(imino)methylamino-1-formyl-(1S)-...) Show SMILES [#6][C@]([#7]-[#6](=O)C(F)(F)F)([#6](=O)-[#7]-1-[#6]-[#6]-[#6@H]-1-[#6](=O)-[#7]-[#6@@H](-[#6]-[#6]-[#6]\[#7]=[#6](\[#7])-[#7])-[#6]=O)c1ccccc1 Show InChI InChI=1S/C21H27F3N6O4/c1-20(13-6-3-2-4-7-13,29-17(33)21(22,23)24)18(34)30-11-9-15(30)16(32)28-14(12-31)8-5-10-27-19(25)26/h2-4,6-7,12,14-15H,5,8-11H2,1H3,(H,28,32)(H,29,33)(H4,25,26,27)/t14-,15-,20+/m0/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	CHEMBL PC cid PC sid UniChem Similars	PubMed	n/a	n/a	9.60	n/a	n/a	n/a	n/a	n/a	n/a
Lilly Research Laboratories Curated by ChEMBL					Assay Description In vitro Enzyme Inhibitory activity against t-PA(Tissue plasminogen activator).				J Med Chem 38: 4446-53 (1995) BindingDB Entry DOI: 10.7270/Q2RB73MV
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298009 (3-[3-(4-fluorobenzyl)-1,2,4-oxadiazol-5-yl]-7-(pip...) Show SMILES Fc1ccc(Cc2noc(n2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1 Show InChI InChI=1S/C20H19FN6O2/c21-14-3-1-12(2-4-14)9-17-24-20(29-26-17)15-11-23-27-16(10-18(28)25-19(15)27)13-5-7-22-8-6-13/h1-4,10-11,13,22H,5-9H2,(H,25,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	9.70	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298237 (3-[3-(2-methoxyphenyl)-1,2,4-oxadiazol-5-yl]-2-met...) Show SMILES COc1ccccc1-c1noc(n1)-c1c(C)nn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C21H22N6O3/c1-12-18(21-24-19(26-30-21)14-5-3-4-6-16(14)29-2)20-23-17(28)11-15(27(20)25-12)13-7-9-22-10-8-13/h3-6,11,13,22H,7-10H2,1-2H3,(H,23,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298073 (3-[5-(2-phenylethyl)-1,3,4-oxadiazol-2-yl]-7-(pipe...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3nnc(CCc4ccccc4)o3)c2[nH]1 Show InChI InChI=1S/C21H22N6O2/c28-18-12-17(15-8-10-22-11-9-15)27-20(24-18)16(13-23-27)21-26-25-19(29-21)7-6-14-4-2-1-3-5-14/h1-5,12-13,15,22H,6-11H2,(H,24,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298184 (Rel-3-{5-[(1R,2S)-2-methylcyclopentyl]-1,2,4-oxadi...) Show SMILES CC1CCCC1c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298246 (3-[3-(4-hydroxybenzyl)-1,2,4-oxadiazol-5-yl]-2-met...) Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(Cc2ccc(O)cc2)no1)C1CCNCC1 Show InChI InChI=1S/C21H22N6O3/c1-12-19(21-23-17(26-30-21)10-13-2-4-15(28)5-3-13)20-24-18(29)11-16(27(20)25-12)14-6-8-22-9-7-14/h2-5,11,14,22,28H,6-10H2,1H3,(H,24,29)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	10	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298253 (3-(cyclopentylcarbonyl)-7-(piperidin-4-yl)pyrazolo...) Show SMILES O=C(C1CCCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C17H22N4O2/c22-15-9-14(11-5-7-18-8-6-11)21-17(20-15)13(10-19-21)16(23)12-3-1-2-4-12/h9-12,18H,1-8H2,(H,20,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298127 (3-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-2-methyl-7-(...) Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nnc(o1)C(C)(C)C)C1CCNCC1 Show InChI InChI=1S/C18H24N6O2/c1-10-14(16-21-22-17(26-16)18(2,3)4)15-20-13(25)9-12(24(15)23-10)11-5-7-19-8-6-11/h9,11,19H,5-8H2,1-4H3,(H,20,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298161 (Cyclobutyl 2-methyl-5-oxo-7-(piperidin-4-yl)-4,5-d...) Show SMILES Cc1nn2c(cc(=O)[nH]c2c1C(=O)OC1CCC1)C1CCNCC1 Show InChI InChI=1S/C17H22N4O3/c1-10-15(17(23)24-12-3-2-4-12)16-19-14(22)9-13(21(16)20-10)11-5-7-18-8-6-11/h9,11-12,18H,2-8H2,1H3,(H,19,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298170 (7-(piperidin-4-yl)-3-(1,2-thiazol-5-yl)pyrazolo[1,...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3ccns3)c2[nH]1 Show InChI InChI=1S/C14H15N5OS/c20-13-7-11(9-1-4-15-5-2-9)19-14(18-13)10(8-16-19)12-3-6-17-21-12/h3,6-9,15H,1-2,4-5H2,(H,18,20)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297845 (5-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3cc(cs3)C#N)c2[nH]1 Show InChI InChI=1S/C16H15N5OS/c17-7-10-5-14(23-9-10)12-8-19-21-13(6-15(22)20-16(12)21)11-1-3-18-4-2-11/h5-6,8-9,11,18H,1-4H2,(H,20,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298096 (2-methyl-3-[3-(4-methylphenyl)-1,2,4-oxadiazol-5-y...) Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccc(C)cc1)C1CCNCC1 Show InChI InChI=1S/C21H22N6O2/c1-12-3-5-15(6-4-12)19-24-21(29-26-19)18-13(2)25-27-16(11-17(28)23-20(18)27)14-7-9-22-10-8-14/h3-6,11,14,22H,7-10H2,1-2H3,(H,23,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298098 (3-(4-ethyl-1,3-thiazol-2-yl)-7-(piperidin-4-yl)pyr...) Show SMILES CCc1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C16H19N5OS/c1-2-11-9-23-16(19-11)12-8-18-21-13(7-14(22)20-15(12)21)10-3-5-17-6-4-10/h7-10,17H,2-6H2,1H3,(H,20,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297791 (Ethyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo...) Show SMILES CCOC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C14H18N4O3/c1-2-21-14(20)10-8-16-18-11(7-12(19)17-13(10)18)9-3-5-15-6-4-9/h7-9,15H,2-6H2,1H3,(H,17,19)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298063 (3-[5-(3-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...) Show SMILES Clc1cccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c1 Show InChI InChI=1S/C20H19ClN6O2/c21-14-3-1-2-12(8-14)9-18-25-26-20(29-18)15-11-23-27-16(10-17(28)24-19(15)27)13-4-6-22-7-5-13/h1-3,8,10-11,13,22H,4-7,9H2,(H,24,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	11	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298238 (3-[3-(2-fluorophenyl)-1,2,4-oxadiazol-5-yl]-2-meth...) Show SMILES Cc1nn2c(cc(=O)[nH]c2c1-c1nc(no1)-c1ccccc1F)C1CCNCC1 Show InChI InChI=1S/C20H19FN6O2/c1-11-17(20-24-18(26-29-20)13-4-2-3-5-14(13)21)19-23-16(28)10-15(27(19)25-11)12-6-8-22-9-7-12/h2-5,10,12,22H,6-9H2,1H3,(H,23,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298114 (3-[(3,3-difluoroazetidin-1-yl)carbonyl]-7-(piperid...) Show SMILES FC1(F)CN(C1)C(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C15H17F2N5O2/c16-15(17)7-21(8-15)14(24)10-6-19-22-11(5-12(23)20-13(10)22)9-1-3-18-4-2-9/h5-6,9,18H,1-4,7-8H2,(H,20,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298037 (3-{5-[4-methyl-2-(trifluoromethyl)phenyl]-1,2,4-ox...) Show SMILES Cc1ccc(-c2nc(no2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)c(c1)C(F)(F)F Show InChI InChI=1S/C21H19F3N6O2/c1-11-2-3-13(15(8-11)21(22,23)24)20-28-18(29-32-20)14-10-26-30-16(9-17(31)27-19(14)30)12-4-6-25-7-5-12/h2-3,8-10,12,25H,4-7H2,1H3,(H,27,31)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297842 ((−)-trans-7-(2-Methylpiperidin-4-yl)-5-oxo-4...) Show SMILES CC1CC(CCN1)c1cc(=O)[nH]c2c(cnn12)C#N Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM92485 (CDE-066 | US9120744, CDE-066) Show SMILES Oc1cc(cc(O)c1O)C(=O)OC[C@H]1OC(OC(=O)c2cc(O)c(O)c(O)c2)[C@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@@H](OC(=O)c2cc(O)c(O)c(O)c2)[C@H]1OC(=O)c1cc(O)c(O)c(O)c1 |r,w:15.16| Show InChI InChI=1S/C41H32O26/c42-17-1-12(2-18(43)28(17)52)36(57)62-11-27-33(64-37(58)13-3-19(44)29(53)20(45)4-13)34(65-38(59)14-5-21(46)30(54)22(47)6-14)35(66-39(60)15-7-23(48)31(55)24(49)8-15)41(63-27)67-40(61)16-9-25(50)32(56)26(51)10-16/h1-10,27,33-35,41-56H,11H2/t27-,33+,34+,35-,41?/m1/s1	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	Purchase PC cid PC sid UniChem Similars	Article PubMed	n/a	n/a	12	n/a	n/a	n/a	n/a	7.8	23
University of Michigan					Assay Description Enzyme activity assay using human and murine PAI-1.				J Biol Chem 285: 7892-902 (2010) Article DOI: 10.1074/jbc.M109.067967 BindingDB Entry DOI: 10.7270/Q2ZC81FC
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297809 (7-(Piperidin-4-yl)-3-(3-propyl-1,2,4-oxadiazol-5-y...) Show SMILES CCCc1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C16H20N6O2/c1-2-3-13-19-16(24-21-13)11-9-18-22-12(8-14(23)20-15(11)22)10-4-6-17-7-5-10/h8-10,17H,2-7H2,1H3,(H,20,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297850 (3-(Phenylsulfonyl)-7-(piperidin-4-yl)pyrazolo[1,5-...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(c2[nH]1)S(=O)(=O)c1ccccc1 Show InChI InChI=1S/C17H18N4O3S/c22-16-10-14(12-6-8-18-9-7-12)21-17(20-16)15(11-19-21)25(23,24)13-4-2-1-3-5-13/h1-5,10-12,18H,6-9H2,(H,20,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	12	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298061 (3-(5-methyl-4-phenyl-1,3-thiazol-2-yl)-7-(piperidi...) Show SMILES Cc1sc(nc1-c1ccccc1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C21H21N5OS/c1-13-19(15-5-3-2-4-6-15)25-21(28-13)16-12-23-26-17(11-18(27)24-20(16)26)14-7-9-22-10-8-14/h2-6,11-12,14,22H,7-10H2,1H3,(H,24,27)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297797 (N-Benzyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyraz...) Show SMILES O=C(NCc1ccccc1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C19H21N5O2/c25-17-10-16(14-6-8-20-9-7-14)24-18(23-17)15(12-22-24)19(26)21-11-13-4-2-1-3-5-13/h1-5,10,12,14,20H,6-9,11H2,(H,21,26)(H,23,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297837 (3-(3-Methoxyphenyl)-7-(piperidin-4-yl)pyrazolo[1,5...) Show SMILES COc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C18H20N4O2/c1-24-14-4-2-3-13(9-14)15-11-20-22-16(10-17(23)21-18(15)22)12-5-7-19-8-6-12/h2-4,9-12,19H,5-8H2,1H3,(H,21,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297824 (4-[5-Oxo-7-(piperidin-4-yl)-4,5-dihydropyrazolo[1,...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3ccc(cc3)C#N)c2[nH]1 Show InChI InChI=1S/C18H17N5O/c19-10-12-1-3-13(4-2-12)15-11-21-23-16(9-17(24)22-18(15)23)14-5-7-20-8-6-14/h1-4,9,11,14,20H,5-8H2,(H,22,24)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297808 (3-(3-Isopropyl-1,2,4-oxadiazol-5-yl)-7-(piperidin-...) Show SMILES CC(C)c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C16H20N6O2/c1-9(2)14-20-16(24-21-14)11-8-18-22-12(7-13(23)19-15(11)22)10-3-5-17-6-4-10/h7-10,17H,3-6H2,1-2H3,(H,19,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	13	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298247 (3-[5-(3-fluoro-4-methoxybenzyl)-1,3,4-oxadiazol-2-...) Show SMILES COc1ccc(Cc2nnc(o2)-c2cnn3c(cc(=O)[nH]c23)C2CCNCC2)cc1F Show InChI InChI=1S/C21H21FN6O3/c1-30-17-3-2-12(8-15(17)22)9-19-26-27-21(31-19)14-11-24-28-16(10-18(29)25-20(14)28)13-4-6-23-7-5-13/h2-3,8,10-11,13,23H,4-7,9H2,1H3,(H,25,29)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298154 (Methyl 5-oxo-7-(piperidin-4-yl)-4,5-dihydropyrazol...) Show SMILES COC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C13H16N4O3/c1-20-13(19)9-7-15-17-10(6-11(18)16-12(9)17)8-2-4-14-5-3-8/h6-8,14H,2-5H2,1H3,(H,16,18)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298177 (3-(5-Cyclopropyl-1,2,4-oxadiazol-3-yl)-7-(piperidi...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CC3)c2[nH]1 Show InChI InChI=1S/C16H18N6O2/c23-13-7-12(9-3-5-17-6-4-9)22-15(19-13)11(8-18-22)14-20-16(24-21-14)10-1-2-10/h7-10,17H,1-6H2,(H,19,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298182 (3-(5-Cyclopentyl-1,2,4-oxadiazol-3-yl)-7-(piperidi...) Show SMILES O=c1cc(C2CCNCC2)n2ncc(-c3noc(n3)C3CCCC3)c2[nH]1 Show InChI InChI=1S/C18H22N6O2/c25-15-9-14(11-5-7-19-8-6-11)24-17(21-15)13(10-20-24)16-22-18(26-23-16)12-3-1-2-4-12/h9-12,19H,1-8H2,(H,21,25)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298065 (3-[5-(2-chlorobenzyl)-1,3,4-oxadiazol-2-yl]-7-(pip...) Show SMILES Clc1ccccc1Cc1nnc(o1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C20H19ClN6O2/c21-15-4-2-1-3-13(15)9-18-25-26-20(29-18)14-11-23-27-16(10-17(28)24-19(14)27)12-5-7-22-8-6-12/h1-4,10-12,22H,5-9H2,(H,24,28)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297825 (3-(3-Chlorophenyl)-7-(piperidin-4-yl)pyrazolo[1,5-...) Show SMILES Clc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C17H17ClN4O/c18-13-3-1-2-12(8-13)14-10-20-22-15(9-16(23)21-17(14)22)11-4-6-19-7-5-11/h1-3,8-11,19H,4-7H2,(H,21,23)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297939 (7-(piperidin-4-yl)-3-{3-[2-(trifluoromethoxy)pheny...) Show SMILES FC(F)(F)Oc1ccccc1-c1noc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C20H17F3N6O3/c21-20(22,23)31-15-4-2-1-3-12(15)17-27-19(32-28-17)13-10-25-29-14(9-16(30)26-18(13)29)11-5-7-24-8-6-11/h1-4,9-11,24H,5-8H2,(H,26,30)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297796 (N-Isobutyl-5-oxo-7-(piperidin-4-yl)-4,5-dihydropyr...) Show SMILES CC(C)CNC(=O)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C16H23N5O2/c1-10(2)8-18-16(23)12-9-19-21-13(7-14(22)20-15(12)21)11-3-5-17-6-4-11/h7,9-11,17H,3-6,8H2,1-2H3,(H,18,23)(H,20,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297798 (3-(Morpholin-4-ylcarbonyl)-7-(piperidin-4-yl)pyraz...) Show SMILES O=C(N1CCOCC1)c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C16H21N5O3/c22-14-9-13(11-1-3-17-4-2-11)21-15(19-14)12(10-18-21)16(23)20-5-7-24-8-6-20/h9-11,17H,1-8H2,(H,19,22)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297815 ((−)-trans-3-Chloro-7-(2-methylpiperidin-4-yl...) Show SMILES CC1CC(CCN1)c1cc(=O)[nH]c2c(Cl)cnn12 Show InChI	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM297847 (7-(Piperidin-4-yl)-3-[3-(trifluoromethoxy)phenyl]p...) Show SMILES FC(F)(F)Oc1cccc(c1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C18H17F3N4O2/c19-18(20,21)27-13-3-1-2-12(8-13)14-10-23-25-15(9-16(26)24-17(14)25)11-4-6-22-7-5-11/h1-3,8-11,22H,4-7H2,(H,24,26)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	14	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298180 (3-[5-(2-Methylprop-1-en-1-yl)-1,2,4-oxadiazol-3-yl...) Show SMILES CC(C)=Cc1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 |(5.75,5.52,;4.26,5.12,;3.17,6.21,;3.86,3.64,;2.37,3.24,;1.9,1.77,;.36,1.77,;-.12,3.24,;1.13,4.14,;-.73,.68,;-2.26,.84,;-2.89,-.56,;-1.75,-1.59,;-1.75,-3.13,;-.41,-3.9,;.92,-3.13,;2.26,-3.9,;.92,-1.59,;-.41,-.82,;-3.08,-3.9,;-4.41,-3.13,;-5.75,-3.9,;-5.75,-5.44,;-4.41,-6.21,;-3.08,-5.44,)| Show InChI InChI=1S/C17H20N6O2/c1-10(2)7-15-21-16(22-25-15)12-9-19-23-13(8-14(24)20-17(12)23)11-3-5-18-6-4-11/h7-9,11,18H,3-6H2,1-2H3,(H,20,24)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	15	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298055 (3-[4-(2-fluorophenyl)-1,3-thiazol-2-yl]-7-(piperid...) Show SMILES Fc1ccccc1-c1csc(n1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C20H18FN5OS/c21-15-4-2-1-3-13(15)16-11-28-20(24-16)14-10-23-26-17(9-18(27)25-19(14)26)12-5-7-22-8-6-12/h1-4,9-12,22H,5-8H2,(H,25,27)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	15	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair
Tissue-type plasminogen activator (Homo sapiens (Human))	BDBM298005 (3-[5-(4-methylphenyl)-1,2,4-oxadiazol-3-yl]-7-(pip...) Show SMILES Cc1ccc(cc1)-c1nc(no1)-c1cnn2c(cc(=O)[nH]c12)C1CCNCC1 Show InChI InChI=1S/C20H20N6O2/c1-12-2-4-14(5-3-12)20-24-18(25-28-20)15-11-22-26-16(10-17(27)23-19(15)26)13-6-8-21-9-7-13/h2-5,10-11,13,21H,6-9H2,1H3,(H,23,27)	PDB MMDB NCI pathway Reactome pathway KEGG UniProtKB/SwissProt B.MOAD DrugBank antibodypedia GoogleScholar AffyNet	PC cid PC sid UniChem	US Patent	n/a	n/a	15	n/a	n/a	n/a	n/a	n/a	n/a
BAYER PHARMA AKTIENGESELLSCHAFT US Patent					Assay Description The clot-lysis test system configures the kinetics of clot formation and degradation in vitro and allows quantifying modulation of the process by sel...				US Patent US10118930 (2018) BindingDB Entry DOI: 10.7270/Q2QC05J5
					More data for this Ligand-Target Pair

Displayed 1 to 50 (of 769 total )  |  Next  |  Last  >>

Jump to: